{"nctId":"NCT00858637","briefTitle":"Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis","startDateStruct":{"date":"2009-03"},"conditions":["Chronic Kidney Disease"],"count":260,"armGroups":[{"label":"1 MCI-196","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-196","Drug: Placebo of Simvastatin"]},{"label":"2 Placebo of MCI-196","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo of Simvastatin","Drug: Placebo of MCI-196"]},{"label":"3 Simvastatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Simvastatin","Drug: Placebo of MCI-196"]},{"label":"4 Placebo of Simvastatin","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo of Simvastatin","Drug: Placebo of MCI-196"]}],"interventions":[{"name":"MCI-196","otherNames":["Colestilan(INN)","Colestimide(JAN)","CHOLEBINE®","BindRen®"]},{"name":"Placebo of Simvastatin","otherNames":[]},{"name":"Simvastatin","otherNames":[]},{"name":"Placebo of MCI-196","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, and is \\>=18 years old\n* Stable hemodialysis or peritoneal dialysis\n* Subjects undergoing regular dialysis treatment\n* If Female and of child-bearing potential, have a negative serum pregnancy test\n* Male subjects must agree to use appropriate contraception\n\nExclusion Criteria:\n\n* Current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose him/her to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study\n* Serum albumin level \\< 30 g/L\n* Triglycerides level \\> 6.76 mmol/L (600 mg/dL)\n* LDL-cholesterol level \\> 4.94 mmol/L (190 mg/dL)\n* A History of significant gastrointestinal motility problems\n* Biliary obstruction or proven liver dysfunction\n* A positive test for HIV 1 and 2 antibodies\n* A history of substance or alcohol abuse within the last year\n* The subject has a history of rhabdomyolysis or myopathy\n* Schedule to receive a kidney transplant within the next 6 months\n* The subject has porphyria\n* Participation in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2)","description":"Percent Change from Week 16 to Week 20 (LOCF)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.03","spread":"19.92"},{"groupId":"OG001","value":"42.55","spread":"30.96"},{"groupId":"OG002","value":"2.76","spread":"18.43"},{"groupId":"OG003","value":"49.84","spread":"41.89"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Serum LDL-cholesterol Levels From Baseline to Week 16 (LOCF) (ITT1)","description":"Percent Change from Baseline to Week 16 (LOCF)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.67","spread":"19.45"},{"groupId":"OG001","value":"-26.38","spread":"22.9"}]}]}]},{"type":"SECONDARY","title":"Change in Phosphorus(P), Calcium(Ca), Calcium-phosphorus Ion Product(PxCa) and Parathyroid Hormone (PTH)","description":null,"classes":[]},{"type":"SECONDARY","title":"Vital Signs, Adverse Events, and Laboratory Values","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":128},"commonTop":["Anaemia","Nausea","Hypotension","Headache","Dyspepsia"]}}}